Summary
Indomethacin 100 mg/day or matching placebo was given for 2.5 days to 9 healthy volunteers in a double-blind cross-over study, followed by an intravenous injection of 0.2 mg/kg of hydralazine. Compared to placebo, indomethacin produced no statistically significant change in pulse rate or blood pressure in both standing and supine positions. Hydralazine injection was followed by a statistically significant fall in lying and standing diastolic pressure and a rise in lying and standing pulse after both indomethacin and placebo pretreatments. There were no significant differences in these effects following indomethacin compared to placebo pretreatment. These results do not support the hypothesis that endogenous prostaglandins are involved in the mechanism of action of hydralazine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Durao V, Prata MM, Goncalves LMP (1977) Modification of anti-hypertensive effect of beta-adrenoceptor blocking agents by inhibition of endogenous prostaglandin synthesis. Lancet 2: 1005–1007
Eklund B, Joretag T, Kaijser L (1981) Dissimilar effects of prostacyclin on cardiac output and forearm blood flow in healthy man. Clin Physiol 1: 123–130
Fitzgerald GA, Friedman LA, Miyamori I, O'Grady J, Lewis PJ (1979) A double-blind placebo controlled cross-over study of prostacyclin in man. Life Sci 25: 665–672
Graham RM, Campbell WB, Jackson EK, Pettinger NA, Loisel DP (1979) Role of prostaglandins in hydralazine-induced renin and catecholamine release in conscious rabbits. Fed Proc 38: 420
Haeusler G, Gerold M (1979) Increased levels of prostaglandin-like material in the canine blood during arterial hypotension produced by hydralazine, dihydralazine and minoxidil. Naunyn-Schmiedebergs Arch Pharmakol 310: 155–167
Hucker HB, Zacchei AG, Cox SV, Brodie DA, Cantwell NHR (1966) Studies on the absorption, distribution and excretion of indomethacin in various species. J Pharmacol Exp Ther 153: 237–249
Lopez-Ovejero JA, Weber MA, Drayer JIM, Seatey JE, Laragh JH (1978) Effects of indomethacin alone and during diuretic or beta adrenoceptor-blockade therapy on blood pressure and the renin system in essential hypertension. Clin Sci Molec Med 55: 203s-205s
Nowak J, Wennmalm A (1978) Influence of indomethacin and of prostaglandin E1 on total and regional blood flow in man. Acta Physiol Scand 102: 484–491
Patak RV, Mookerjee BK, Bentzel CJ, Hysert PE, Babej M, Le JB (1975) Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man. Prostaglandins 10: 649–659
Rubin LJ, Lazar JD (1981) Influence of prostaglandin synthesis inhibitors on pulmonary vasodilatory effects of hydralazine in dogs with hypoxic pulmonary vasoconstriction. J Clin Invest 67: 193–200
Slack BL, Warner ME, Keiser HR (1978) The effect of prostaglandin synthetase inhibition on the action of hydralazine. Circulation 58 [Suppl 2] Abstract 21
Steiness E, Waldorff S (1982) Different interactions of indomethacin and sulindac with thiazides in hypertension. Br Med J 285: 1702–1703
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for asprin-like drugs. Nature (New Biol) 231: 232–235
Watkins J, Abbott EC, Hensby CN, Webster J, Dollery CT (1980) Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin. Br Med J 281: 702–705
Wennmalm A (1978) Influence of indomethacin on the systemic and pulmonary vascular resistance in man. Clin Sci Molec Med 54: 141–145
Wennmalm A, Eriksson S, Hagerfeldt L, Law D, Patrono C, Pinca E (1983) Effect of prostaglandin synthesis inhibitors on basal and carbon dioxide stimulated cerebral blood flow in man. In: Samuelsson B, Paoletti R, Ramwell PW (eds) Advances in prostaglandin, thromboxane and leukotriene research, vol 12. Raven Press, NY
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jackson, S.H.D., Pickles, H. Indomethacin does not attenuate the effects of hydralazine in normal subjects. Eur J Clin Pharmacol 25, 303–305 (1983). https://doi.org/10.1007/BF01037938
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01037938